Anandamide: An endogenous cannabinoid

Drugs of Today

Volumn 32, Issue 4, 1996, Pages 275-285

  Kulkarni, S K ^a   Ninan, I ^a   George, B ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; RECEPTOR SUBTYPE;

BEHAVIOR; BIOSYNTHESIS; BRAIN; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG METABOLISM; HISTOCHEMISTRY; HUMAN; MOLECULAR CLONING; NONHUMAN; REVIEW; SWINE;

EID: 0029943405     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Iversen, L.L. Medical uses of marijuana. Nature 1993, 365: 12-3.
2. Gray, C. Cannabis - The therapeutic potential. Pharmaceut J 1995, 254: 771-3.
3. William, D.L. Cannabinoid pharmacology. Pharmacol Rev 1986, 38: 151-78.
4. Razdan, R.K. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986, 38: 75-149.
5. Devane, W.A., Dysarz, F.A., Johnson, M.R., Melvin, L.S., Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34: 605-13.
6. Compton, D.R., Rice, K.C., Costa, B.R. et al. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activation. J Pharmacol Exp Ther 1993, 265: 218-26.
7. Herkenham, M., Lynn, A., Johnson, M.R., Melvin, L.S., Costa, B., Rice, K. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991, 11: 563-83.
8. William, D.L., Hanus, L., Breuer, A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258: 1946-9.
9. William, D.L. New dawn on cannabinoid pharmacology. Trends Pharmacol Sci 1994, 15: 40-1.
10. Hanus, L., Gopher, A., Almog, S., Mechoulam, R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993, 36: 3032-4.
11. Ehlert, F.J., Roeske, W.R., Gee, K.W., Yamamura, H.I. An allosteric model for benzodiazepine receptor function. Biochem Pharmacol 1983, 32: 2375-83.
12. Evans, D.M., Johnson, M.R., Howlett, A.C. Calcium-dependent release from rat brain of cannabinoid receptor binding activity. J Neurochem 1992, 58: 780-2.
13. David, E.M., Lake, T., Johnson, R.M., Howlett, A.C. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J Pharmacol Exp Ther 1994, 268: 1271-7.
14. Hansen, H.S. New biological and clinical roles for the n-6 and n-3 fatty acids. Nutrition Rev 1994, 52: 162-7.
15. William, A.D., Julius, A. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 1994, 91: 6698-701.
16. Kruszka, K.K., Gross, R.W. The ATP- and CoA-independent synthesis of arachidonyl ethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J Biol Chem 1994, 269: 14345-8.
17. Dimarzo, V., Fontana, A., Cadas, H. et al. Formation and inactivation of endogenous cannabinoid, anandamide in central neurons. Nature 1994, 372: 686-91.
18. Veda, N., Yamamoto, K., Yamamoto, S. et al. Lipoxygenase-catalysed oxygenation of arachidonyl ethanolamide, a cannabinoid receptor agonist. Biochem Biophys Acta 1995, 1254: 127-34,
19. Dale, G.D., Auzette, A.C. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993, 46: 791-6.
20. Lester, M., Kelly, K.Y., Chen, B., Almira, M. The effect of cannabinoid on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem Biophys Res Commun 1993, 197: 740-6.
21. Koutak, B., Prestwich, G.D., Howlett, A.C. et al. Inhibitors of arachidonyl ethanolamide hydrolysis. J Biol Chem 1994, 269: 22937-40.
22. Smith, P.B., David, R.C., Sandra, P., Razdan, R.K., Raphael, M., Martin, B. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994, 270: 219-27.
23. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., De Costa, B.R., Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991, 11: 563-81.
24. Matsuda, L.A., Bonner, T.I., Lolait, S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993, 327: 535-50.
25. Gerard, C.M., Mollereau, C., Vassart, G., Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991, 279: 129-34.
26. Munro Kerrie, L., Muna, A.S. Molecular characterization of peripheral receptor for cannabinoids. Nature 1993, 365: 61-5.
27. Matsuda, L.A., Stephen, J.L., Michael, J., Young, C., Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346: 561-4.
28. Howlett, A.C. Reverse pharmacology applied to the cannabinoid receptor. Trends Pharmacol Sci 1990, 11: 395-7.
29. Miles, H., Allison, B.L., Mark, D.L., Johnson, R.M., Lawrence, S., Rice, K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990, 87: 1932-6.
30. Fride, E., Raphael, M. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993, 231: 313-4.
31. Howlett, A.C. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995, 35: 607-34.
32. Facci, L., Toso, R., Buriani, A., Skaper, S.D., Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995, 92: 3376-80.
33. Jack, D.B. An exciting new approach to inflammation. Mol Med Today 1995, 1: 158.
34. Rinaldi, C.M., Barth, F., Heaulme, M. et al. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350: 240-4.
35. 9-THC modulates antigen processing by macrophages. J Pharmacol Exp Ther 1995, 273: 1216-23.
36. Burstein, H., Charlene, A., Breuer, A., William, A., Colodner, S., Raphael, M. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic and leukocyte antiadhesion activities. J Med Chem 1992, 35: 3135-41.
37. Felder, C.C., Veluz, J.S., Williams, H.L., Briley, E.M., Matsuda, L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 1992, 42: 838-45.
38. Vogel, Z., Jacob, B., Levy, R., Danielle, S., Heldman, E., Raphael, M. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 1993, 61: 352-5.
39. Mackie, K., Devane, W.A., Hille, B. Anandamide, an endogenous cannabinoid inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. J Neurochem 1992, ?: 1754-9.
40. Baumgold, J., Paek, R., Fiskum, G. Calcium independence of phosphoinositol hydrolysis-induced increase in cAMP accumulators in SK-N-SH human neuroblastoma cells. Mol Pharmacol 1993, 44: 86-90.
41. Jones, S.V., Heilman, C.J., Brann, M.R. Functional responses of cloned muscarinic receptors expressed in CHO-Ki cells. Mol Pharmacol 1991, 40: 242-7.
42. i-protein β, γ subunits. Nature 1992, 356: 159-61.
43. Goa, B., Gilman, A.G. Cloning and expression of a widely distributed (type-IV) adenyl cyclase. Proc Natl Acad Sci USA 1991, 88: 10178-82.
44. Tang, W.J., Gilman, A.G. Type specific regulation of adenyl cyclase by G-protein β, γ subunits. Science 1991, 254: 1500-3.
45. Bakalyar, H.A., Reed, R.R. Identification of a specified adenyl cyclase that may mediate odorant detection. Science 1990, 250: 1403-4.
46. Russell, M., Devane, W.A., Howlett, A.C. Cannabinoid receptors and modulators of cyclic AMP accumulation in the rat brain. J Neurochem 1990, 55: 21-6.
47. Howlett, A.C. Cannabinoid inhibition of adenylate cyclase, relative activity of constituents and metabolites of marihuana. Neuropharmacology 1987, 26: 507-12.
48. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346: 561-4.
49. Mackie, K., Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992, 89: 3825-9.
50. l in the inhibition of adenylate cyclase by cannabinomimetic drugs. Mol Pharmacol 1986, 29: 507-12.
51. Devane, W.A., Breuer, A., Sheskin, T., Torbjorn, U.C.J., Moris, S.E., Mechoulam, R. A novel probe for the cannabinoid receptor. J Med Chem 1992, 35: 2065-9.
52. Felder, C.C., Briley, E.M., Julius, A., Simpson, J.T., Mackie, K., William, A.D. Anandamide, an endogenous cannabinomimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993, 90: 7656-60.
53. Mackie, K., Devane, W.A., Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 1993, 44: 498-503.
54. Hoyer, D., Boddeke, W.G.M. Partial agonists, full agonists, antagonists: Dilemmas of definition. Trends Pharmacol Sci 1993, 14: 270-5.
55. 11-THC reduces its cataleptic effect in mice. Experientia 1987, 43: 402-3.
56. Burstein, S., Hull, K., Hunter, S.A., Latham, V. Cannabinoids and responses: A possible role for prostaglandins. FASEB J 1988, 2: 3022-6.
57. Burstein, S. Eicosanoids as mediators of cannabinoid action. In: Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Murphy, L., Barke, A. (Eds.). CRC Press: Ann Arbor 1992, 73-90.
58. Tenakin, T. Agonist, partial agonist, antagonists, inverse antagonists and agonist/antagonist? Trends Pharmacol Sci 1987, 8: 423-6.
59. Haefely, W., Martin, J.R., Schoch, P. Novel anxiolytics that act as partial agonist at benzodiazepine receptors. Trends Pharmacol Sci 1990, 11: 452-6.
60. Takayanagim I., Koike, K., Nakagoshi, S. β-Adrenergic partial agonists and two different affinity sites in β-adrenoreceptors. In: Recent Research on Neurotransmitter Receptors. Yoshida, H. (Ed.). Excerpta Medica: Amsterdam 1986, 41-52.
61. Bonetti, C.P., Pole, P., Laurent, J.P., Schoch, P., Haefely, W. Clonazepam is a partial agonist at the benzodiazepine receptors. Neuroscience 1987, Suppl. S82.
62. Gilman, A.G. G-proteins and dual control of adenylate cyclase. Cell 1984, 36: 577-9.
63. Bidaut, R., Devane, W.A., Howlett, A.C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem 1990, 55: 21-6.
64. Howlett, A.C., Evans, D.M., Houston, D.B. The cannabinoid receptor. In: Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Murphy, L., Bartke, A. (Eds.). CRC Press: Ann Arbor 1992, 35-72.
65. l in the inhibition of adenylate cyclase by cannabinomimetic drugs. Mol Pharmacol 1986, 29: 307-13.
66. Johnson, D.E., Heald, S.L., Dally, R.D., Janis, R.A. Isolation, identification and synthesis of an endogenous arachidonic amide that inhibits calcium channel antagonists 1,4-dihydropyridine binding. Prostagland Leuk Essent Fatty Acids 1993, 48: 429-37.
67. Pinto, J.C., Potie, F., Rice, K.C. et al. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 1994, 46: 516-22.
68. Irma, B., William, R., Singer, M. et al. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 1995, 273: 1172-81.
69. l that amplifies ATP-mediated arachidonic acid release. Proc Natl Acad Sci USA 1991, 88: 6477-80.
70. Pertwee, R.G. The ring test: A quantitative method for assessing the cataleptic effect of cannabis in mice. Brit J Pharmacol 1972, 46: 753-63.
71. 9-THC and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur J Pharmacol 1993, 250: 205-8.
72. 9-THC-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 1988, 27: 485-91.
73. Pertwee, R.G., Wickens, A.P. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991, 30: 237-44.
74. 9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 1988, 27: 1265-70.
75. Abadji, V., Lin, S., Taha, G. et al. (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994, 37: 1989-93.
76. Sandra, P.W. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N- , N - diallyl - tyrosine - Aib - phenylalanine - leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 1993, 265: 633-40.
77. Herbert, S., Goldstein, E., Raphael, M., Arthur, M., Selmam, Z. Anandamide, a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci USA 1994, 91: 7678-82.
78. Weindenfeld, J., Feldman, S., Mechoulam, R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994, 59: 110-2.
79. 9-THC-induced antinociception. J Pharmacol Exp Ther 1995, 273: 1235-44.
80. 9-THC and the cannabinomimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Brit J Pharmacol 1993, 110: 1483-90.